Sood Aditya, Kotamarti Vasanth S, Therattil Paul J, Lee Edward S
The Ohio State University Medical Center, Department of Plastic and Reconstructive Surgery, Columbus, OH, USA.
Rutgers New Jersey Medical School, Division of Plastic and Reconstructive Surgery, Newark, NJ, USA.
Eplasty. 2017 Aug 28;17:e25. eCollection 2017.
Despite improved recognition of risk factors, plastic surgeons commonly encounter seromas postoperatively and must decide upon management. Current recommendations for minimally invasive, chemical management originate from the literature on management of pneumothorax and pleural effusions. A handful of published reports have suggested the efficacy of sclerotherapy in seroma management. The aim of this study was to assess the literature on the use of sclerosants to treat subcutaneous fluid collections. A systematic review of the literature was performed on the PubMed, MEDLINE, and Cochrane databases for primary research articles on sclerotherapy for seroma treatment between January 1975 and January 2017. Exclusion criteria were surgical treatment, sclerotherapy for seroma prevention, hematoma, or absence of detailed documentation. Data related to seroma location, sclerosant, and resolutions were extracted. The literature search yielded 7 relevant articles of level IV evidence and 12 case reports, with a total of 84 patients treated with sclerotherapy for persistent seromas. Slerosant included talc, tetracycline antibiotics, ethanol, polidocanol, erythromycin, OK-432, fibrin glue, and povidone-iodine. All agents achieved high rates of success. Repeat aspirations and instillations were easily performed when required. Complications, while uncommon, included pain, tightness or discomfort of the treated area, and infection. Sclerotherapy appears to be effective and safe for recurrent seromas. While a variety of sclerosing agents may be applied successfully, talc and tetracyclines remain popular choices. Because of the small scale and retrospective nature of the published literature, larger, randomized, comparative studies are necessary to assess and optimize this treatment approach.
尽管对危险因素的认识有所提高,但整形外科医生在术后仍经常遇到血清肿,必须决定如何处理。目前关于微创化学治疗的建议源于气胸和胸腔积液治疗的文献。少数已发表的报告表明硬化疗法在血清肿治疗中有效。本研究的目的是评估使用硬化剂治疗皮下积液的文献。对PubMed、MEDLINE和Cochrane数据库进行了系统的文献综述,以查找1975年1月至2017年1月间关于硬化疗法治疗血清肿的原发性研究文章。排除标准为手术治疗、预防血清肿的硬化疗法、血肿或缺乏详细记录。提取了与血清肿位置、硬化剂和消退情况相关的数据。文献检索产生了7篇IV级证据的相关文章和12篇病例报告,共有84例患者接受了硬化疗法治疗持续性血清肿。硬化剂包括滑石粉、四环素类抗生素、乙醇、聚多卡醇、红霉素、溶链菌制剂、纤维蛋白胶和聚维酮碘。所有药物均取得了很高的成功率。必要时可轻松进行重复抽吸和注入。并发症虽不常见,但包括治疗区域的疼痛、紧绷或不适以及感染。硬化疗法对复发性血清肿似乎有效且安全。虽然多种硬化剂均可成功应用,但滑石粉和四环素仍然是常用的选择。由于已发表文献的规模较小且具有回顾性,因此需要进行更大规模的随机对照研究来评估和优化这种治疗方法。